Study of EC0225 for the Treatment of Refractory or Metastatic Tumors

Inclusion Criteria: * 18 years of age or older * Histological or cytological diagnosis of neoplasm * No effective standard therapeutic options * ECOG performance status of 0-2 * ≥ to 4 weeks post therapeutic radiation or chemotherapy(≥ to 6 weeks for nitrosureas) and recovery (to baseline status) from associated acute toxicities. Patients previously treated with non-cytotoxic therapy and who have recovered from or have controlled drug-associated toxicity are allowed to enter the trial after a period consisting of 4 half-lives of the agent. * Negative serum pregnancy test for women of child-bearing potential within one week prior to treatment with investigational agents (99mTc-EC20 and EC0225) * Adequate bone marrow reserve, renal and hepatic function Exclusion Criteria: * Concurrent malignancies * Women who are pregnant or lactating * Evidence of symptomatic brain metastases * Receiving concomitant anticancer therapy (excluding supportive care) * Requires palliative radiotherapy at time of study entry * Unable to tolerate conditions for radionuclide imaging * Administration of another radiopharmaceutical that would interfere with assessment of 99mTc-EC20